Emilie Lemasle
Emilie Lemasle is an expert in Hematology at Centre Henri Becquerel (France). Emilie Lemasle has authored 72 publications, the most recent in 2026, and is an investigator in 26 clinical trials, 14 of them ongoing. SLR score: 411 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Oncology - Cardiology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2011 - 2026
Number : 72
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Real-world patterns of treatment intensity and prognostic model performance in older acute myeloid leukemia: insights from the French ALFA-PPP Cohort. PMID 42581243 — leukemia, leukemia, myeloid, acute, public-private sector partnerships, leukemia, myeloid, therapeutics | Leukemia | 2026 | 0 |
| Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy. PMID 42166362 — cells, genes, hematology, leukemia, drug therapy, leukemia, myeloid, acute, leukemia, myeloid, chemotherapy | Blood | 2026 | 0 |
| Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial. PMID 41135009 — precursor cell lymphoblastic leukemia-lymphoma, hematology, leukemia, drug therapy, aged, transplants, therapeutics, chemotherapy | Blood | 2025 | 0 |
| Intermediate-Dose Cytarabine as Postinduction AML Therapy. PMID 40552969 — cytarabine, therapeutics | NEJM Evid | 2025 | 0 |
| Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid Disorders. PMID 40162927 — cells, neoplasms, leukemia, leukemia, myeloid, acute, clonal evolution, leukemia, myeloid, therapeutics, clone cells, mutation | Clin Cancer Res | 2025 | 0 |
Clinical Studies 26
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
14 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Multicenter Open Label Dose Finding Clinical Trial to Assess the Safety Pharmacokinetics Pharmacodynamics and Clinical Efficacy of RVU120 in Combination with Venetoclax in Participants with Acute Myeloid Leukemia Who Failed Prior Therapy with Venetoclax and a Hypomethylating Agent (RIVER 81) 2023-505911-19-00 — safety, rivers, leukemia, leukemia, myeloid, acute, leukemia, myeloid, therapeutics, pharmacokinetics | Phase 2 | Recruiting | 2024 |
| Open label phase II study evaluating the efficacy and safety of the combination of tagraxofusp and venetoclax in treatment naive blastic plasmacytoid dendritic cell neoplasm patients 2024-511003-42-00 — skin, cells, safety, neoplasms, therapeutics, dendritic cells | Phase 2 | Recruiting | 2025 |
| A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy 2024-512753-24-00 — genes, leukemia, drug therapy, leukemia, myeloid, acute, azacitidine, leukemia, myeloid, therapeutics, chemotherapy | Phase 3 | Not yet recruiting | 2025 |
| FILOAML RR 01 OGILAR Open label phase 2 study investigating the efficacy and safety of the addition of oral azacitidine to salvage treatment by gilteritinib in subjects 18 years of age with relapsed refractory FLT3 mutated acute myeloid leukemia 2022-501372-25-00 — safety, leukemia, recycling, leukemia, myeloid, acute, aged, azacitidine, leukemia, myeloid, therapeutics, salvage therapy | Phase 2 | Active not recruiting | 2024 |
| Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg ) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation in Complete Remission After Intensive Chemotherapy NCT07463768 — safety, leukemia, tablets, drug therapy, leukemia, myeloid, acute, azacitidine, leukemia, myeloid, therapeutics, mutation, chemotherapy | Phase 2 | Not yet recruiting | 2026 |
LeadR Networks
Main global connection map